Name: Egfr-Directed Therapy in Lung Cancer (Elements in Molecular Oncology) (en Inglés)
SKU: 54489865
Price: 678.47 MXN
Availability: InStock
Author: Kim, So Yeon ; Costa, Daniel B. ; Shibahara, Daisuke
ISBN: 9781009342308

portada Egfr-Directed Therapy in Lung Cancer (Elements in Molecular Oncology) (en Inglés)

Egfr-Directed Therapy in Lung Cancer (Elements in Molecular Oncology) (en Inglés)

Formato

Libro Físico

Autor

So Yeon Kim

Daniel B. Costa

Daisuke Shibahara

Editorial

Cambridge University Press

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

Dimensiones

22.9x15.2x0.2 cm

Peso

0.07 kg.

ISBN13

9781009342308

N° edición

Categorías

Oncología

Egfr-Directed Therapy in Lung Cancer (Elements in Molecular Oncology) (en Inglés)

So Yeon Kim (Autor) · Daniel B. Costa (Autor) · Daisuke Shibahara (Autor) · Cambridge University Press · Tapa Blanda

Libro Nuevo Importado

Envío: 18 a 23 días háb.

$ 1,356.93$ 678.47

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

$ 678.47

¡Envío Gratis! Llega entre el 15 Oct y el 23 Oct a CUAUHTÉMOC, Ciudad de México. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Egfr-Directed Therapy in Lung Cancer (Elements in Molecular Oncology) (en Inglés)"

Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).